Objectives

After participating in this educational activity, attendees should be able to:

1. Explain the mechanism and effects of vaso-occlusive crises (VOC) in patients with sickle cell disease.
2. Describe the usual management of VOC as based on guideline recommendations.
3. Summarize prior data on the use of ketamine in sickle cell vaso-occlusive crises.
4. Discuss the study by Alshahrani, et al. and how it may affect current practice and management of VOC.

Faculty

Hannah Ritchie, PharmD
PGY2 Critical Care Pharmacy Resident
Pharmacist
Baystate Medical Center 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Pharmacists
Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.